Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
Prashant Gajwani1, David J Muzina2, David E Kemp3, Keming Gao1, Joseph R Calabrese11Case Western Reserve University (CWRU) School of Medicine, 2Cleveland Clinic Lerner College of Medicine of CWRU, 3Case Western Reserve University, Cleveland OH, USAAbstract: The essential features of bipolar affectiv...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2007-01-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Online Access: | http://www.dovepress.com/update-on-quetiapine-in-the-treatment-of-bipolar-disorder-results-from-a963 |
| _version_ | 1818406173948248064 |
|---|---|
| author | Prashant Gajwani David J Muzina David E Kemp Keming Gao Joseph R Calabrese |
| author_facet | Prashant Gajwani David J Muzina David E Kemp Keming Gao Joseph R Calabrese |
| author_sort | Prashant Gajwani |
| collection | DOAJ |
| description | Prashant Gajwani1, David J Muzina2, David E Kemp3, Keming Gao1, Joseph R Calabrese11Case Western Reserve University (CWRU) School of Medicine, 2Cleveland Clinic Lerner College of Medicine of CWRU, 3Case Western Reserve University, Cleveland OH, USAAbstract: The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same.Keywords: bipolar disorder, quetiapine, BOLDER studies |
| first_indexed | 2024-12-14T09:07:44Z |
| format | Article |
| id | doaj.art-05c22c74891d4858a3d09afe0db2ebd1 |
| institution | Directory Open Access Journal |
| issn | 1176-6328 1178-2021 |
| language | English |
| last_indexed | 2024-12-14T09:07:44Z |
| publishDate | 2007-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj.art-05c22c74891d4858a3d09afe0db2ebd12022-12-21T23:08:39ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212007-01-012007Issue 6847853Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studiesPrashant GajwaniDavid J MuzinaDavid E KempKeming GaoJoseph R CalabresePrashant Gajwani1, David J Muzina2, David E Kemp3, Keming Gao1, Joseph R Calabrese11Case Western Reserve University (CWRU) School of Medicine, 2Cleveland Clinic Lerner College of Medicine of CWRU, 3Case Western Reserve University, Cleveland OH, USAAbstract: The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same.Keywords: bipolar disorder, quetiapine, BOLDER studieshttp://www.dovepress.com/update-on-quetiapine-in-the-treatment-of-bipolar-disorder-results-from-a963 |
| spellingShingle | Prashant Gajwani David J Muzina David E Kemp Keming Gao Joseph R Calabrese Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies Neuropsychiatric Disease and Treatment |
| title | Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies |
| title_full | Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies |
| title_fullStr | Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies |
| title_full_unstemmed | Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies |
| title_short | Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies |
| title_sort | update on quetiapine in the treatment of bipolar disorder results from the bolder studies |
| url | http://www.dovepress.com/update-on-quetiapine-in-the-treatment-of-bipolar-disorder-results-from-a963 |
| work_keys_str_mv | AT prashantgajwani updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT davidjmuzina updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT davidekemp updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT keminggao updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT josephrcalabrese updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies |